Ross-shire Journal23m
GSK lifts long-term sales targets on new drug pipeline
Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline. It ...
GSK Plans £2 Billion Share Buyback, Boosts Long-term Outlook
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.The British drugmaker boosted its 2031 sales forecast to ...
FTSE 100 giant GSK eyes more than £40bn in sales by 2031
Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than ...
GSK Expects Further Profit Growth After Beating Market Views
The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...
GSK beats Q4 earnings estimates, lifts 2031 sales target
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
UBS Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...